AP2011005978A0 - 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. - Google Patents

2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.

Info

Publication number
AP2011005978A0
AP2011005978A0 AP2011005978A AP2011005978A AP2011005978A0 AP 2011005978 A0 AP2011005978 A0 AP 2011005978A0 AP 2011005978 A AP2011005978 A AP 2011005978A AP 2011005978 A AP2011005978 A AP 2011005978A AP 2011005978 A0 AP2011005978 A0 AP 2011005978A0
Authority
AP
ARIPO
Prior art keywords
diaminopyrimidines
excessive
treatment
cell proliferation
abnormal cell
Prior art date
Application number
AP2011005978A
Other languages
English (en)
Inventor
Daniel Kuhn
Ioannis Sapountzis
Heinz Stadtmueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2011005978A0 publication Critical patent/AP2011005978A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2011005978A 2009-05-29 2010-05-28 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. AP2011005978A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09161496 2009-05-29
EP10161628 2010-04-30
PCT/EP2010/057408 WO2010136559A1 (en) 2009-05-29 2010-05-28 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation

Publications (1)

Publication Number Publication Date
AP2011005978A0 true AP2011005978A0 (en) 2011-12-31

Family

ID=42289495

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005978A AP2011005978A0 (en) 2009-05-29 2010-05-28 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.

Country Status (22)

Country Link
US (1) US8410126B2 (xx)
EP (1) EP2435411B1 (xx)
JP (1) JP5756799B2 (xx)
KR (1) KR20120135010A (xx)
CN (1) CN102448943A (xx)
AP (1) AP2011005978A0 (xx)
AR (1) AR076620A1 (xx)
AU (1) AU2010251943A1 (xx)
BR (1) BRPI1014994A2 (xx)
CA (1) CA2763700A1 (xx)
CL (1) CL2011003022A1 (xx)
CO (1) CO6470899A2 (xx)
EA (1) EA201101674A1 (xx)
EC (1) ECSP11011558A (xx)
IL (1) IL216084A0 (xx)
MA (1) MA33302B1 (xx)
MX (1) MX2011012643A (xx)
PE (1) PE20120370A1 (xx)
SG (1) SG176599A1 (xx)
TW (1) TW201107308A (xx)
UY (1) UY32673A (xx)
WO (1) WO2010136559A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146981A2 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3475263B1 (en) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
WO2019190259A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
US20220332711A1 (en) * 2021-04-02 2022-10-20 Bridge Biotherapeutics, Inc. N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408727A1 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP4460292B2 (ja) 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
AU2003244098A1 (en) * 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (en) * 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111023A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
CA2673125C (en) * 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SG2014015085A (en) * 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors

Also Published As

Publication number Publication date
IL216084A0 (en) 2012-01-31
CN102448943A (zh) 2012-05-09
MA33302B1 (fr) 2012-05-02
US20110130401A1 (en) 2011-06-02
JP2012528121A (ja) 2012-11-12
CA2763700A1 (en) 2010-12-02
UY32673A (es) 2010-12-31
ECSP11011558A (es) 2012-01-31
MX2011012643A (es) 2011-12-14
EP2435411A1 (en) 2012-04-04
JP5756799B2 (ja) 2015-07-29
US8410126B2 (en) 2013-04-02
CL2011003022A1 (es) 2012-07-13
TW201107308A (en) 2011-03-01
AU2010251943A1 (en) 2011-12-01
BRPI1014994A2 (pt) 2016-05-03
PE20120370A1 (es) 2012-05-09
AR076620A1 (es) 2011-06-22
EA201101674A1 (ru) 2012-06-29
CO6470899A2 (es) 2012-06-29
EP2435411B1 (en) 2014-10-29
KR20120135010A (ko) 2012-12-12
SG176599A1 (en) 2012-01-30
WO2010136559A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
IL260117A (en) Use of placental cells to treat diseases, syndromes or conditions of the lungs
IL255752B (en) Compounds, pharmaceutical preparations containing the same uses for the treatment of cardiovascular disease, inflammatory diseases and cancer
MY172372A (en) Compositions and methods for lowering triglycerides
WO2010058032A3 (en) Substituted pyrimidines for the treatment of diseases such as cancer
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
EP2432476A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
HRP20130357T1 (xx) Novi spojevi, korisni za lijeäśenje degenerativnih i upalnih bolesti
MY160241A (en) 5-alkynyl-pyrimidines
ZA201201222B (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
IN2012DN02471A (xx)
ZA201005384B (en) Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
TN2011000531A1 (en) 5- alkynyl - pyridines
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
WO2010083240A9 (en) Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
EP2387565A4 (en) 2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
IN2012DN01846A (xx)
SI2473492T1 (sl) Postopek za pripravo(1S,4R)-2-oksa-3-azabiciklo(2.2.1)hept-5-enov
TN2011000049A1 (en) 5-alkynyl-pyrimidines
TN2010000463A1 (en) Compositions and methods for preparing and using same
TN2010000408A1 (en) Thiazolyl-dihydro-indazoles
GB0821490D0 (en) Molecular methods for the treatment of disease.